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As programs move closer toward the World Health Organization (WHO) goals of reduction in morbidity, elimination as a public health 
problem or elimination of transmission, countries will be faced with planning the next stages of surveillance and control in low prevalence 
settings. Mathematical models of neglected tropical diseases (NTDs) will need to go beyond predicting the effect of different treatment 
programs on these goals and on to predicting whether the gains can be sustained. One of the most important challenges will be identifying 
the policy goal and the right constraints on interventions and surveillance over the long term, as a single policy option will not achieve all 
aims—for example, minimizing morbidity and minimizing costs cannot both be achieved. As NTDs move toward 2030 and beyond, more 
nuanced intervention choices will be informed by quantitative analyses which are adapted to national context.
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Transmission dynamic modeling has been used in recent years 
to evaluate the effectiveness of ongoing and alternative treat-
ment programs for reducing the global burden of the neglected 
tropical diseases (NTDs) [1, 2]. In late 2020, the World Health 
Organization (WHO) Roadmap [3] for NTDs was approved by 
the World Health Assembly and maps the way forward to 2030 
with measurable targets for the reduction in morbidity and 
mortality of the NTDs. As programs move closer to these tar-
gets and toward ambitious more targets, the next phase in mod-
eling NTDs will require predictions of indicators of resurgence, 
sustained transmission, and elimination alongside measures of 
cost, effort, and health outcomes.
The planning of longer term NTD programs will depend on 
the goal of elimination. This may be elimination of transmis-
sion, also referred to as interruption of transmission, which is 
achieved when there is zero incidence of the NTD in a defined 
geographic area [4]. Eradication is the permanent reduction to 
zero incidence. The feasibility of eradication for NTDs will be 
disease specific [5]. Similarly, WHO has defined disease specific 
goals, including, for several diseases defined as Elimination as a 
Public Health Problem (EPHP), meaning that the public health 
impact of these diseases has been reduced, even if transmission 
continues.
The feasibility of reaching and maintaining these goals will 
depend on the quality of the surveillance system in detecting 
new cases. For lymphatic filariasis, new cases have been found 
after an EPHP target threshold has been met [6], and there is 
evidence to suggest that a more intensive, and likely more costly 
surveillance threshold of <1% microfilaria (mf) prevalence, 
may not be enough to achieve elimination of transmission in 
some areas [7]. The 2030 target for schistosomiasis is EPHP [3], 
but modeling has shown that once morbidity or EPHP goals 
have been achieved, the goals may be maintained at lower ef-
forts; however, there is also risk of resurgence in some settings 
where control efforts are reduced [8].
Most NTDs are characterized by very slow epidemic 
growth rates, but robust surveillance is required to ensure 
that cases are identified. To achieve greater certainty in 
prevalence or incidence, more effort, and hence more cost, 
is required. If such surveillance programs could identify 
increasing case numbers and subsequently aid in preventing 
resurgence, cases and costs would be averted in the future 
by triggering a public health response. However, for NTDs, 
this causes 2 challenges. First will there be the political will 
and budget available for responsive interventions, and can 
we calculate the cost of, for example, relaunching a locally 
targeted, effective mass drug administration in several years’ 
time? Second, as prevalence of NTDs becomes smaller, the 
cost of surveillance programs may increase to the extent 
where it may outweigh any cost of having sustained the inter-
vention—for example, maintaining MDA versus surveillance 
to confirm that elimination has been achieved. The option 
then may not be an immediate goal elimination or eradica-
tion but a sustainable control system to maintain goals that 
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have already been achieved. Such a system would have robust 
surveillance and response, due to the slow epidemic growth 
rates, that would be able to gradually achieve elimination and 
eradication but on a longer timescale and without the addi-
tional immediate investment to achieve elimination. The re-
sult would be a response that is manageable both in terms of 
cost and effort and more likely to be successful.
Transmission dynamic modeling can be used to evaluate the 
effectiveness of long-term surveillance programs in identifying 
likelihood or resurgence. The predicted performance of surveil-
lance programs can be evaluated using model predictions while 
accounting diagnostic uncertainty, and these predictions can 
be combined with costs to develop models for sustainable con-
trol. In this article we discuss the steps toward developing such 
models and the challenges that accompany them (Figure 1).
SURVEY DESIGN AND STATISTICAL METHODOLOGY
As programs move toward elimination, maximizing informa-
tion given limited resources will aid in targeting treatment and 
identifying possible areas of resurgence. Who and when to 
sample in survey design should be informed by the duration 
of infectiousness and whether there are high-risk groups [9]. 
Research is needed to evaluate the effectiveness of potential 
alternative surveillance strategies. For example, research into 
understanding the capability of molecular xenomonitoring for 
detecting presence of lymphatic filariasis (LF) in human popu-
lations [10] and serology for visceral leishmaniasis (VL) in 
south Asia [11]. Additionally, exploring predictions at different 
geographic scales will aid in program planning; for example, 
one analysis suggests that the geographical   scale of decision 
making  affects the number of people that will require treatment 
for onchocerciasis [12].
Survey design must also be revaluated under the premise 
of limited resources, such as integrated surveillance [13], ex-
ploring survey designs, to optimize resource use in monitoring 
the drug efficacy for treating soil transmitted helminths and 
schistosomiasis [14] or utilising model-based geostatistics to 
optimise survey design and analysis [15]. Development of sta-
tistical tools will be complemented by mathematical models of 
underlying transmission dynamics.
CONNECTING MODELS TO DATA: TRANSMISSION 
DYNAMICS AND IMPERFECT DATA
Mathematical models, once validated with data, can be used 
to predict infection dynamics after treatment programs have 
been stopped. These data, however, are a snapshot of under-
lying infection dynamics, arising from case detection of a subset 
of the population and often via imperfect diagnostic testing. 
Understanding the uncertainty arising from these observation 
processes will be critical to understanding whether elimination 
has truly occurred or whether treatment should be re-started. 
For example, recent model predictions of an increase in tra-
chomatous inflammation–follicular (TF) prevalence after MDA 
has stopped could represent true resurgence or measurement 
error [16].
Figure 1. Conceptual framework describing the components of developing dynamic models and the respective challenges. The model is both informed by data and must 
predict data by accounting for diagnostic uncertainty. Model predictions and costs will inform the multicriteria evaluation of sustainable control programs.
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Imperfect diagnostic testing at low prevalence levels could 
also impact triggering of surveillance thresholds. A  high 
number of false positives due to low specificity could result in 
a program being restarted incorrectly. Whereas a high number 
of false negatives due to low sensitivity could result in a pro-
gram not being restarted, when in fact the program needs to 
be restarted. Models have been used to show that a decreased 
detection effort resulted in a decrease of observed VL incidence 
but an increase in the true incidence [17]. Mathematical models 
designed to connect predictions to data on the same scale and 
measure as the survey is designed to collect can be used to un-
derstand the identifiability of these outcomes and also to predict 
the impact on resurgence probability if the incorrect outcome is 
assumed to be true.
In addition, there is role for mathematical models in sur-
veillance to assess the effectiveness of new diganostic tools 
or alternative control measures, such as vector control for 
LF [18]. Some diagnostic tests perform poorly in low trans-
mission settings and so may not be suitable for in programs 
with a goal of elimination [19] whereas others may be useful 
for monitoring co-endemic areas [20]. In this collection, 
model-based assessments of the use of both microfilaremia 
and antigenemia data in predicting elimination of transmis-
sion of LF following MDA are presented. Models also have 
a role in evaluating the usefulness of new diagnostic tests 
in surveillance. For example, one analysis explores the rela-
tionship between occurrence of new VL cases and predicted 
biomarker prevalence, highlighting the potential role of 
population-based surveys for monitoring risk of VL resur-
gence [21].
For some NTDs, the underlying biological or epidemiological 
assumptions are not fully understood. The most informative age 
group for seromonitoring of onchocerciasis is influenced by the 
model assumptions of age-dependent exposure and the optimal 
threshold of seroprevalence for monitoring onchocerciasis trans-
mission is influenced by model assumptions of density-dependent 
parasite establishment [22]. In addition, the model assumptions 
of the underlying biology and age-structured prevalence of soil-
transmitted helminth affects the control effort required to reach 
the 2030 morbidity targets [23]. These model-based predictions 
were used to propose different program designs to account for 
such sources of uncertainty [23]. Understanding both structural 
uncertainty and observation uncertainty will be key to utilizing 
models to predict the dynamics of elimination.
CONNECTING MODELS TO PREDICTIONS: 
INDICATORS OF RESURGENCE AND EFFECTIVENESS 
METRICS
Model predictions can be used to calculate effectiveness 
metrics to determine whether treatment can be reduced or 
stopped. Model-based thresholds of elimination can be cal-
culated using either a deterministic model-based threshold, 
which if reached, elimination is certain (referred to as a crit-
ical threshold in [24]) or a stochastic model-based threshold. 
Stochastic model-based thresholds can be determined by cal-
culating the certainty of elimination by using the proportion 
of eliminations detected by the threshold statistic that result 
in long-term eliminations [25]. Stochastic models have been 
used to determine model-based thresholds while accounting 
for diagnostic testing uncertainty [25].
Modeling has shown that resurgence can occur outside 
of the current recommended postintervention surveil-
lance period for LF [26] and that higher coverage active 
screenings gives more certainty of elimination of transmis-
sion of gambiense human African trypanosomiasis in the 
future [27]. To achieve EPHP of Schistosoma mansoni and 
Schistosoma haematobium, community-wide treatment, in-
stead of only treating school-aged children, is required in 
high transmission settings or in settings with low school en-
rollment [28]. In addition, the probability of sustaining the 
morbidity control goal of S.  mansoni under different treat-
ment strategies depends on transmission intensity and the 
level of adult burden [8].
Using prevalence alone is not always a sufficient measure of 
potential for onward transmission. Predicting the probability 
of elimination may be improved by using prevalence difference 
over multiple years instead of current prevalence only [26]. 
Although snapshots of TF prevalence do not directly relate to 
underlying transmissibility, TF prevalence over time can be 
used to detect hotspots of transmission that may benefit from 
increased treatment coverage [29].
It is important, however, to distinguish effectiveness metrics 
to minimize or maximize depending on whether we wish to 
monitor which subpopulations may contribute to onward trans-
mission from the individuals with the greatest risk of morbidity. 
An appropriate metric to minimize onward transmission may 
be a particular age group: for example, the role of school-aged 
children in trachoma transmission [30] or individuals with high 
worm burden in schistosomiasis transmission [31]. However, 
these groups may not also have the highest risk of morbidity.
As many NTDs result in morbidity, disability-adjusted life 
years (DALYs) averted are commonly used as metrics of effec-
tiveness [32]. However, DALYs may not always be an appro-
priate measure for all individuals. For example, DALYs of an 
average infection do not take into account the complicated 
burden of high intensity infections of schistosomiasis [31]. 
Turner et al [31] calculate 3 different effectiveness metrics that 
capture the effect of treatment for schistosomiasis on both par-
asite transmission (overall worm burden) and morbidity (prev-
alent infection case years averted and heavy case years averted). 
Different treatment programs cannot be simply planned ac-
cording to simple effectiveness metrics of low, medium, or high 
prevalence; other disease- and setting-specific factors must be 
considered. Modelers will need to distinguish the metrics of 
S132 • cid 2021:72 (Suppl 3) • Minter et al
transmission potential and the metrics of morbidity as we move 
towards models aimed at maintaining the gains.
COMBINING COSTS AND PREDICTIONS FOR 
DECISION MAKING
As programs move toward low prevalence settings, countries will 
need to decide whether to continue to survey areas or stop sur-
veillance. In these cases, they will also need to decide if they need 
to trigger the restart of treatment programs. Thresholds of active 
and passive surveillance after treatment has stopped will need to 
be defined. We can assume a passive surveillance threshold will 
be higher than any active surveillance threshold, but quantifying 
these thresholds will be challenging. Also, it is likely that in the 
timescale of NTD elimination, thresholds of detection may in-
crease as diseases become rarer.
Given these surveillance thresholds, programs of active or 
passive surveillance will need to be costed. Unlike traditional 
cost-effective analysis, in models with sustainable control, costs 
will not remain constant over time. This can be achieved either 
through trying to reach final cases [32], restarting treatment 
programs, or implementation of new diagnostic tools [19]. 
Hence the total cost over a time horizon should be calculated 
[32], where the choice of time horizon should be informed by 
the duration of infectiousness. Costs will also vary across set-
tings [19], as will the functional form of the costs over time. 
Therefore, we should not seek a generalizable cost function or 
values but to develop a framework to guide that process [19].
 Model predictions and effectiveness measures could be con-
nected to program costs to evaluate the cumulative cost and 
health impact of resurgence or elimination under different sur-
veillance programs. We must also consider the role that these 
models will have in equity of health. The optimal model for 
EPHP given monetary costs may suggest stopping treatment 
and switching to passive surveillance with a likelihood of some 
individuals in the population still being infected.
CHALLENGES TO MODELING 
SUSTAINABLE CONTROL
Modeling sustainable control programs will entail multiple chal-
lenges. First, the mathematical models that will be used to calcu-
late effectiveness metrics are poorly validated at low prevalence. 
Model validation at these low prevalence settings will need to take 
place, but the timescale of this validation will be at odds with the 
timescale for control recommendations. If a model is validated at 
this low prevalence, imperfect diagnostic testing may lead to diffi-
culties in distinguishing between true elimination and false nega-
tives. Modeling these observation processes will help accounting 
for uncertainty, but some outcomes, especially at low prevalence, 
may not be identifiable from each other.
Costs will likely be country specific, not just in terms of abso-
lute costs but also relative to their economy. Ensuring all costs 
are accounted for appropriately will require collaboration with 
stakeholders and health economists. In addition, there may be 
barriers to successful surveillance or treatment that should be 
included in a modeling framework. For example, programs may 
have the drugs for treatment but do not have the resources to 
deliver them [19].
CONCLUSIONS
As programs head toward the 2030 goals, transmission models 
will need to predict the impact of passive or reduced surveil-
lance in low prevalence settings, quantify the effect of imper-
fect diagnostic testing on the dynamics of elimination, include 
country-specific thresholds for detection, and describe the 
competing costs and health impacts associated with different 
surveillance and responsive intervention programs.
Mathematical models and statistical methodology could have 
a role to play in decision making for maintaining the gains in 
elimination programs. Understanding the spatial heterogeneity 
in disease prevalence and adaptation to local circumstances will 
be critical for the sustainability of control measures. Newly de-
veloped statistical tools will be used quantify prevalence given 
limited resources and identify hotspots of transmission. In this 
article, we have summarized the key components and associ-
ated challenges with developing models in the next phase of 
NTD elimination goals (Figure 1). The optimal program will 
depend on the country and disease-specific goal; therefore, 
modelers must collaborate with the stakeholders and decision 
makers so that modeling can be utilized to maintain the gains.
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